From: "Domingo Kent" <Emery318@yahoo.com>
To: <paliourg@iit.demokritos.gr>
Subject: Re [9] Buy this Stock TTTP
Date: Sun, 16 May 2004 11:07:12 +0300
MIME-Version: 1.0
Content-Type: text/html;
	charset="iso-8859-7"
Content-Transfer-Encoding: quoted-printable
X-Priority: 3
X-MSMail-Priority: Normal
X-MimeOLE: Produced By Microsoft MimeOLE V6.00.2900.2527

<HTML><HEAD><TITLE>Re[8] Investor Alert  TTTP on the move</TITLE>
<BODY>
<DIV align=3Djustify>
<TABLE borderColor=3D#ffffff cellPadding=3D15 width=3D650 align=3Dcenter =
border=3D0>
  <TBODY>
  <TR>
    <TD vAlign=3Dtop width=3D650>
      <DIV align=3Dcenter><FONT face=3DTahoma color=3D#006633 =
size=3D6><FONT=20
      =
color=3D#000099><STRONG>TTTP*****TTTP*****TTTP*****TTTP</STRONG></FONT>=20
      </FONT></DIV>
      <P align=3Dcenter><FONT face=3DTahoma color=3D#990000 =
size=3D6><STRONG><EM>ST0CK=20
      FINDER NEWSLETTER</EM> </STRONG></FONT></P>
      <P align=3Dcenter><FONT face=3DTahoma color=3D#333333 =
size=3D5>Wants to inform=20
      aggressive invest<FONT size=3D4>0</FONT>rs of a company that we =
feel is=20
      extremely undervalued and poised for gr<FONT=20
      size=3D4>0</FONT>wth</FONT><FONT color=3D#333333 size=3D4><FONT=20
      face=3DTahoma><STRONG><BR></STRONG></FONT></FONT></P>
      <P align=3Dcenter><FONT face=3DTahoma color=3D#000099 =
size=3D4><FONT=20
      size=3D6><STRONG>12 to 20 Plus Inc (OTCBB:TTTP) =
</STRONG></FONT></FONT></P>
      <P align=3Dcenter><FONT face=3DTahoma color=3D#000099 =
size=3D5><STRONG>Fiscal Year=20
      End: Dec 31<BR>52 Week High: $.25<BR>Shares 0utstanding : 30=20
      Million<BR>Shares in the Public Float: 4 =
Million</STRONG></FONT></P>
      <P align=3Dcenter><FONT face=3DTahoma color=3D#000099 =
size=3D4><STRONG><FONT=20
      size=3D5>TARGET PRICE IN NEXT 3-5 DAYS: $0.75 - 0.80<BR>TARGET =
PRICE IN NEXT=20
      10 DAYS: $0.92 </FONT></STRONG></FONT></P>
      <P align=3Dcenter><FONT face=3DTahoma color=3D#000099=20
      size=3D4><STRONG><BR></STRONG></FONT></P>
      <P align=3Dcenter><FONT face=3DTahoma color=3D#990000 =
size=3D5><STRONG><EM>The=20
      Company</EM></STRONG></FONT> </P>
      <P align=3Djustify><FONT face=3DTahoma color=3D#333333 size=3D4>12 =
to 20 Plus,=20
      Inc. (OTCBB: TTTP) is a late stage development company that =
produces and=20
      markets (through its Neurochemical Research Group division) highly =

      effective condition-specific supplements, often referred to as=20
      neutraceuticals.<BR></FONT></P>
      <P align=3Dcenter><FONT face=3DTahoma size=3D5><STRONG><EM><FONT=20
      color=3D#990000>The Products</FONT></EM></STRONG></FONT></P>
      <P align=3Djustify><FONT face=3DTahoma color=3D#333333 =
size=3D4>Manufactured by=20
      FDA-approved labs, contain a sophisticated combination of =
extensively=20
      researched nutritional elements and do not contain herbs. Retail =
sales in=20
      the explosive dietary supplement market are expected to hit $40 =
billion by=20
      the year 2007, according to Frost &amp; Sullivan reports. =
Marketing=20
      research, product development, Beta testing and various mergers =
and=20
      acquisitions in 2003, has now positioned 12 to 20 Plus (TTTP) to =
roll out=20
      its full product line consisting of 7 products of which they have =
their=20
      own proprietary formula, into the multi-billion dollar Over the =
Counter=20
      (OTC) market. 12 To 20 Plus is ready to capitalize on its =
exceptional=20
      product line.</FONT></P>
      <P align=3Djustify>&nbsp;</P>
      <P align=3Dcenter><FONT face=3DTahoma color=3D#990000 =
size=3D5><STRONG><EM>Key=20
      Facts about 12 to 20 Plus Inc</EM></STRONG></FONT></P>
      <P align=3Djustify><FONT face=3DTahoma size=3D3><STRONG>- They =
have introduced 9=20
      products to the market that the company owns the proprietary =
rights to,=20
      products that have been produced in FDA approved =
labs.</STRONG></FONT></P>
      <P align=3Djustify><STRONG><FONT face=3DTahoma size=3D3>- One of =
their products=20
      Anaplex (antidepressant) is currently being sold =
and<BR>distributed in=20
      Longs Drug Stores, one of America's leading drug stores with over =
400=20
      stores</FONT></STRONG></P>
      <P align=3Djustify><STRONG><FONT face=3DTahoma size=3D3>- The =
company is=20
      negotiating deals with two major distributors in Europe for their=20
      healthcare products.</FONT></STRONG></P>
      <P align=3Djustify><STRONG><FONT face=3DTahoma size=3D3>- They are =
currently in=20
      process of attempting to market one their newest products a =
revolutionary=20
      re-hydration product to the U.S Military and to allied forces=20
      overseas.</FONT></STRONG></P>
      <P align=3Dcenter><FONT face=3DTahoma size=3D3><FONT =
color=3D#990000=20
      size=3D5><STRONG><EM>The Industry</EM></STRONG></FONT></FONT></P>
      <P align=3Djustify><FONT face=3DTahoma size=3D3><FONT =
size=3D4><FONT=20
      color=3D#333333>The neutraceutical sector has experienced some =
great growth=20
      over the past five years, being capped off in 2002 when revenues =
for the=20
      global nutrition markets hit $160 billion. United States took=20
      responsibility for about 1/3 of that, with $56.5 billion, 18.5 =
coming from=20
      the nutrition markets, $19.8 from functional foods, and $4.4 =
billion from=20
      personal care products. It's safe to say that globally we are =
looking for=20
      new ways to live healthier and longer lives, and that =
pharmaceutical=20
      remedies could quickly be a thing of the =
past.</FONT></FONT></FONT></P>
      <P align=3Djustify><FONT face=3DTahoma color=3D#333333 =
size=3D4>It's estimated=20
      that 95% of medical doctors` practices entail writing =
pharmaceutical=20
      prescriptions and that 50% of these prescriptions are to treat the =
side=20
      effects of medications being utilized to treat the specific =
ailment.=20
      People are no longer neglecting the facts that what they are =
putting into=20
      their bodies, may not be good for them, medicinal foods or =
"nutritionally=20
      high powered foods" have been in the natural products industry for =
a long=20
      time and through emerging scientific research the public interest =
has the=20
      reached the mainstream.</FONT></P>
      <P align=3Djustify><FONT face=3DTahoma color=3D#333333 size=3D4>It =
seems as though=20
      everywhere you look these days the talk is on dieting whether it =
be the=20
      low carbohydrate/high protein Atkins diet, The Zone diet, or any =
of the=20
      other millions of options we have, the world is concerned with =
weight.=20
      According to the American Obesity Association, of adults over the =
age of=20
      20 in the United States 127 million are overweight, 60 million are =
obese,=20
      and 9 million are severely obese. Obesity increases the risk of =
illness=20
      from 30 serious medical conditions. This fact is forcing many of =
the snack=20
      food and soft drink companies to come up with new healthier =
products that=20
      meet the taste standards of today's consumers.</FONT></P>
      <P align=3Djustify>&nbsp;</P>
      <P align=3Dcenter><FONT face=3DTahoma color=3D#990000=20
      size=3D5><EM><STRONG>Comparable companies in this=20
      Sector</STRONG></EM></FONT></P>
      <P align=3Djustify><FONT face=3DTahoma color=3D#333333 size=3D4>- =
USANA Health=20
      Sciences Inc (Nasdaq:USNA) current price $27.39 - Nutraceutical=20
      International Corp (Nasdaq:NUTR) current price $25.97 - Vital =
Living Inc=20
      (OTCBB:VTLV) current price $.68</FONT></P>
      <P align=3Djustify>&nbsp;</P>
      <P align=3Dcenter><FONT face=3DTahoma color=3D#990000=20
      size=3D3><STRONG><EM>Dis<FONT color=3D#999999=20
      size=3D1>.</FONT>claimer</EM></STRONG></FONT></P>
      <P align=3Djustify><FONT face=3DTahoma size=3D2>This contains =
f<FONT=20
      size=3D1>0</FONT>rward-l<FONT size=3D1>00</FONT>king statements =
within the=20
      meaning of The Private Securities Litigation Reform Act of 1995. =
These=20
      statements may be identified by such terms as expect", "believe", =
"may",=20
      "will", "explode","move","undervalued" and "intend" or similar =
terms. The=20
      information in the above statement could not be 100% accurate and =
the=20
      newsletter is not responsible for this. We are NOT a registered =
investment=20
      advisor or a broker dealer. This is NOT an offer to buy or sell=20
      securities. No recommendation that the securities of the companies =

      profiled should be purchased, sold or held by individuals or =
entities that=20
      learn of the profiled companies. This newsletter was paid $3000 in =
cash by=20
      third--party to publish this report.Investing in companies =
profiled is=20
      high-risk and use of this information is for reading purposes =
only. If=20
      anyone decides to act as an investor, then it will be that =
investor's sole=20
      risk. Investors are advised NOT to invest without the proper =
advertisement=20
      from an attorney or a registered financial broker. Do not rely =
solely on=20
      the information presented,do additional independent research to =
form your=20
      own opinion and decision regarding investing in the profiled =
companies. Be=20
      advised that the purchase of such high-risk securities may result =
in the=20
      loss of your entire investment. Void where prohibited. The owners =
of this=20
      publication or their partners may already own free trading shares =
in TTTP=20
      and may immediately sell all or a the time this date stated and =
are=20
      subject to change without=20
notice.<BR></FONT></P></TD></TR></TBODY></TABLE></DIV></BODY></HTML>

